Annual exams are more crucial than ever as the prevalence of chronic diseases in the United States continues to climb.

The Cyprus Association of Liver Patients "Promitheas" launched a new information campaign on Friday, focusing on the risks ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

A commission proposed a new definition of obesity focused on how excess fat affects the body, rather than assessing body mass ...

About Allurion Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss ... The Allurion Gastric Balloon is an investigational device in the United States. For more information ...

BROWNSVILLE — It was an unusually cold Saturday morning in the Rio Grande Valley but that didn't stop hundreds of people from forming a line that wound throughout the south side of the Brownsville ...

Michael W. Schwartz UW Medicine Diabetes Institute, explains how the brain can be targeted to treat obesity and diabetes ...

This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a ...

NYSE:ALUR) Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity ...

TUESDAY, Jan. 21, 2025 (HealthDay News) -- Black people with obesity are less likely to get weight-loss surgery than others.

Swissmedic has taken legal action against media for alleged unauthorised advertising of weight-loss drugs. Swiss media say this is censorship.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...